Castration-Resistant Prostate Cancer trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Castration-Resistant Prostate Cancer. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month5 studies across 4 companies, in the next 180 days.
August 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| EXEL | Exelixis | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsNCT03845166Dose-Escalation Stage: MTD/recommended dose for XL092 | Phase 1 | Active, not recruiting | 2026-08-31 | in 11 d | 2024-11-19 |
| NRIX | Nurix Therapeutics, Inc. | A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs | Phase 1 | Recruiting | 2026-08-31 | in 11 d | 2025-09-09 |
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.NCT06629779Radiographic Progression Free Survival (rPFS) | Phase 3 | Recruiting | 2026-12-02 | in 104 d | 2026-08-14 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| EXEL | Exelixis | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) | Phase 1 | Recruiting | 2027-01-31 | in 164 d | 2026-08-05 |
February 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)NCT06380738observationalTime to treatment discontinuation | — | Recruiting | 2027-02-14 | in 178 d | 2026-07-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Castration-Resistant Prostate Cancer
most recently updated first103 studies match. Showing the first 100 of 103 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerNCT03732820results2023-06-15Number of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment | Phase 3 | Active, not recruiting | Drug: olaparib, abiraterone acetate | Metastatic Castration-resistant Prostate Cancer | 895 | 2018-10-31 | 2021-07-30actual | — | 2026-08-18 |
| PFE | Pfizer | $155.3B | Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPCNCT03395197results2024-01-17Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Occuring Within the First 66 Days of Dosing - Part 1 | Phase 3 | Active, not recruiting | Drug: Talazoparib with enzalutamide, Placebo with enzalutamide | mCRPC | 1,054 | 2017-12-18 | 2022-10-03actual | — | 2026-08-17 |
| KYNB | Kyntra Bio | $28M | A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT06842498Radiographic Progression-free Survival (rPFS) By Investigator Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) Criteria | Phase 2 | Recruiting | Drug: FG-3246 | Metastatic Castration-Resistant Prostate Cancer | 75 | 2026-02-22 | 2028-03-31 | in 589 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.NCT06629779Radiographic Progression Free Survival (rPFS) | Phase 3 | Recruiting | Drug: PF-06821497, Placebo, Enzalutamide | Metastatic Castration-Resistant Prostate Cancer | 900 | 2024-10-22 | 2026-12-02 | in 104 d | 2026-08-14 |
| AZN | AstraZeneca | — | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)NCT05489211Objective response rate (ORR) | Phase 2 | Recruiting | Drug: Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, Cisplatin | Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer | 454 | 2022-09-06 | 2027-10-01 | in 407 d | 2026-08-13 |
| JANX | Janux Therapeutics | $1.0B | Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)NCT05519449Incidence of Dose Limiting Toxicities (DLT) | Phase 1 | Recruiting | Biological: JANX007 · Drug: Darolutamide | Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer | 272 | 2022-09-15 | Jul 2027 | ≤ 345 d | 2026-08-13 |
| AMGN | Amgen | $229.9B | A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerNCT07213674OS | Phase 3 | Recruiting | Drug: Xaluritamig, Abiraterone acetate, Docetaxel, Cabazitaxel | Metastatic Castration-resistant Prostate Cancer | 750 | 2025-11-28 | 2030-01-07 | in 1,236 d | 2026-08-13 |
| MGNX | MacroGenics | $261M | A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest. | Phase 1 | Recruiting | Biological: MGC026 Dose Escalation, MGC026 Dose for Expansion | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC) | 250 | 2024-03-06 | May 2028 | ≤ 650 d | 2026-08-11 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate CancerNCT06067841Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: BMS-986460 | Metastatic Castration-resistant Prostate Cancer | 140 | 2023-10-18 | 2029-08-24 | in 1,100 d | 2026-08-10 |
| JANX | Janux Therapeutics | $1.0B | Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate CancerNCT07545811Incidence of Dose Limiting Toxicities (DLTs) | Phase 1 | Recruiting | Biological: JANX014 | Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer | 43 | 2026-04-15 | May 2028 | ≤ 650 d | 2026-08-10 |
| AMGN | Amgen | $229.9B | Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate CancerNCT07493512Number of Participants with Treatment-emergent Adverse Events | Phase 1 | Recruiting | Drug: Xaluritamig | Metastatic Castration-resistant Prostate Cancer (mCRPC) | 40 | 2026-04-28 | 2028-01-30 | in 528 d | 2026-08-07 |
| EXEL | Exelixis | $13.2B | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) | Phase 1 | Recruiting | Drug: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab, Nivolumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail | Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI) | 1,394 | 2021-12-14 | 2027-01-31 | in 164 d | 2026-08-05 |
| REGN | Regeneron Pharmaceuticals | $76.1B | REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell CarcinomaNCT07594106Occurrence of Dose Limiting Toxicities (DLTs) | Phase 1/2 | Recruiting | Drug: REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336 | Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | 265 | 2026-07-20 | 2030-10-27 | in 1,529 d | 2026-08-05 |
| GLUE | Monte Rosa Therapeutics, Inc | $1.3B | Study of Oral MRT-2359 With Apalutamide in Prostate CancerNCT07745361Assess the efficacy of MRT-2359 combined with apalutamide | Phase 2 | Recruiting | Drug: Oral MRT-2359, Apalutamide | Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma) | 25 | Aug 2026 | Oct 2027 | ≤ 437 d | 2026-08-04 |
| PFE | Pfizer | $155.3B | A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaNCT03460977Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD) | Phase 1 | Recruiting | Drug: Mervometostat (PF-06821497), Enzalutamide, Itraconazole | Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL) | 453 | 2018-04-17 | 2028-04-20 | in 609 d | 2026-07-29 |
| ORIC | ORIC Pharmaceuticals | $1.4B | A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)NCT07723248Radiographic Progression Free Survival assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) | Phase 3 | Recruiting | Drug: Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel | Metastatic Castration Resistant Prostate Cancer | 600 | Jul 2026 | Mar 2028 | ≤ 589 d | 2026-07-23 |
| BNTX | BioNTech SE | — | A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate CancerNCT07365995rPFS assessed by BICR | Phase 3 | Recruiting | Drug: BNT324, Docetaxel, Prednisone/prednisolone | Metastatic Castration-resistant Prostate Cancer | 736 | 2026-04-22 | Feb 2031 | ≤ 1,653 d | 2026-07-20 |
| AZN | AstraZeneca | — | Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)NCT06380738observationalTime to treatment discontinuation | — | Recruiting | — | Metastatic Castration-resistant Prostate Cancer | 250 | 2024-02-14 | 2027-02-14 | in 178 d | 2026-07-17 |
| AKTS | Aktis Oncology, Inc. | — | A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate CancerNCT07581184Occurrence of adverse events by severity and occurrence of serious adverse events (SAEs) in participants who received [225Ac]Ac-AKY-2519 | Phase 1 | Recruiting | Drug: [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging) | Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC, B7H3 | 138 | Jul 2026 | Dec 2027 | ≤ 498 d | 2026-07-14 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other TumorsNCT03972657Incidence and severity of Treatment-Emergent Adverse Events (TEAEs) | Phase 1/2 | Recruiting | Drug: REGN5678, Cemiplimab | Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | 345 | 2019-08-12 | 2027-11-15 | in 452 d | 2026-07-09 |
| AZN | AstraZeneca | — | AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)NCT07611110Radiographic Progression-Free Survival (rPFS) | Phase 3 | Recruiting | Drug: AZD2265, Cabazitaxel, Abiraterone, Enzalutamide, Apalutamide, Darolutamide, Rezvilutamide, Radium-223 | Metastatic Castration-resistant Prostate Cancer | 670 | 2026-05-04 | 2029-02-13 | in 908 d | 2026-07-01 |
| AZN | AstraZeneca | — | PROLONG (PRostateOLaparibONcombinationGcc) StudyNCT07674121observationalEvaluate the time to treatment discontinuation (TTD) or death (event-free rate) at 6 and 12 months in 1L NHA pre-exposed mCRPC patients treated with Olaparib + Abiraterone. | — | Not yet recruiting | Drug: Olaparib and Abiraterone Combination | Metastatic Castration-resistant Prostate Cancer (mCRPC) | 75 | 2026-06-30 | 2029-09-30 | in 1,137 d | 2026-06-29 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based ChemotherapyNCT03641560results2025-01-23Number of Participants With Treatment- Emergent Adverse Events (TEAEs) | Phase 4 | Completed | Drug: Enzalutamide, Androgen deprivation therapy (ADT) | Metastatic Castration Resistant Prostate Cancer | 52 | 2018-09-19 | 2024-02-20actual | — | 2026-06-24 |
| AZN | AstraZeneca | — | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)NCT05171816results2025-06-29Radiological Progression Free Survival (rPFS) | Phase 3 | Active, not recruiting | Drug: olaparib, abiraterone acetate | Metastatic Castration-resistant Prostate Cancer | 110 | 2021-06-24 | 2024-01-22actual | — | 2026-06-18 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesNCT07503808Safety and tolerability of IDE034 in Part 1 dose escalation | Phase 1 | Recruiting | Drug: IDE034 | Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer | 150 | 2026-02-24 | 2027-07-30 | in 344 d | 2026-06-18 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate CancerNCT06318273Percentage of Participants With Adverse Events (AEs) | Phase 1 | Active, not recruiting | Drug: ABBV-969 | Metastatic Castration-Resistant Prostate Cancer | 152 | 2024-03-08 | May 2027 | ≤ 284 d | 2026-06-17 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid TumorsNCT07540572Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation | Phase 1 | Recruiting | Drug: IDE574, Fulvestrant injection | ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma | 160 | 2026-03-17 | 2030-03-30 | in 1,318 d | 2026-06-16 |
| AZN | AstraZeneca | — | PRostate Olaparib Real World Evidence StudyNCT06031805observationalTime to treatment discontinuation (TTD) | — | Recruiting | — | Metastatic Castration-resistant Prostate Cancer | 300 | 2023-10-11 | 2028-10-13 | in 785 d | 2026-06-02 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate CancerNCT07189403Number of Participants Reporting Dose-limiting Toxicities (DLTs), Treatment-emergent Adverse Events (TEAEs), TEAEs Associated With Treatment Discontinuation, Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESI) - All Patients | Phase 1 | Recruiting | Drug: DS9051b | Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer | 40 | 2025-11-04 | 2028-03-01 | in 559 d | 2026-05-22 |
| CORT | Corcept Therapeutics | $12.8B | Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate CancerNCT03437941results2026-05-15Number of Patients With One or More Dose-Limiting Toxicity (DLT) | Phase 1/2 | Terminatedsponsor's stated reason: The level of benefit observed did not justify enrolling patients in the Dose Expansion phase of the study. | Drug: Exicorilant, Enzalutamide, Placebo | Metastatic Castration-Resistant Prostate Cancer | 39 | 2018-02-20 | 2021-10-13actual | — | 2026-05-15 |
| AMGN | Amgen | $229.9B | Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)NCT06691984Overall Survival (OS) | Phase 3 | Active, not recruiting | Drug: Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel | Metastatic Castration-resistant Prostate Cancer | 707 | 2024-12-09 | 2029-01-02 | in 866 d | 2026-05-15 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT07244341Part 1: Number of participants with Dose-Limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: Valemetostat, Darolutamide | Metastatic Castration-resistant Prostate Cancer | 60 | 2025-12-03 | 2028-01-31 | in 529 d | 2026-05-15 |
| AZN | AstraZeneca | — | A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate CancerNCT06879041Number of participants with adverse event (AEs) | Phase 1 | Recruiting | Drug: AZD2287, AZD2275, AZD2284 | Metastatic Castration-Resistant Prostate Cancer | 136 | 2025-03-10 | 2029-04-16 | in 970 d | 2026-05-12 |
| XNCR | Xencor, Inc. | $1.9B | XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate CancerNCT05005728Incidence of treatment-emergent adverse events (safety and tolerability of vudalimab) | Phase 2 | Completed | Combination product: vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab + docetaxel, vudalimab + cabazitaxel or docetaxel · Biological: vudalimab monotherapy | Metastatic Castration-Resistant Prostate Cancer | 72 | 2021-10-22 | 2025-06-10actual | — | 2026-05-05 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate CancerNCT05125016Incidence of Dose-Limiting Toxicities (DLTs) | Phase 1/2 | Recruiting | Drug: REGN4336, REGN5678 | Metastatic Castration-resistant Prostate Cancer | 228 | 2021-11-30 | 2030-03-28 | in 1,316 d | 2026-05-05 |
| AZN | AstraZeneca | — | Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 MutationsNCT05457257results2025-12-19Radiological Progression-free Survival - Based on Blinded Independent Central Review (BICR) | Phase 4 | Active, not recruiting | Drug: olaparib, enzalutamide, abiraterone acetate, Prednisone | Metastatic Castration-resistant Prostate Cancer | 43 | 2022-07-29 | 2024-10-22actual | — | 2026-04-21 |
| CELC | Celcuity Inc | $4.6B | Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate CancerNCT06190899Phase 1: Assessment of the safety and tolerability of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC) | Phase 1/2 | Recruiting | Drug: Gedatolisib, Darolutamide | mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease, Prostatic Neoplasms, Castration-Resistant, Prostate Cancer | 54 | 2024-01-01 | Jan 2028 | ≤ 529 d | 2026-04-13 |
| RADX | Radiopharm Theranostics, Ltd | — | A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPCNCT07259213Incidence of treatment emergent adverse events of 161Tb RAD402 (phase 1) (Safety) | Phase 1/2 | Recruiting | Drug: 161Tb RAD402 | Castration-resistant Prostate Cancer | 73 | 2026-03-05 | 2028-11-30 | in 833 d | 2026-04-01 |
| RADX | Radiopharm Theranostics, Ltd | — | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsNCT07189871Recommended dose(s) of 177Lu-BetaBart for future exploration (phase 1) | Phase 1/2 | Recruiting | Drug: 177Lu-BetaBart | Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC) | 61 | 2026-02-23 | Dec 2027 | ≤ 498 d | 2026-03-27 |
| INMB | Inmune Bio, Inc. | $59M | Study of INKmune in Patients With mCRPC (CaRe Prostate)NCT06056791Determine the optimal concentration of INKmune therapy to be used in patients with mCRPC. | Phase 1/2 | Completed | Biological: INKmune | Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC | 12 | 2023-11-30 | 2025-09-10actual | — | 2026-02-27 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate CancerNCT05968599results2026-02-25observationalOverall Survival (OS): Adjusted Using Inverse Probability Treatment Weighting (IPTW) | — | Completed | Drug: Enzalutamide, Abiraterone acetate | Prostatic Neoplasms, Castration-Resistant | 2,731 | 2023-07-24 | 2025-02-14actual | — | 2026-02-25 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid TumorsNCT02744287Dose Limiting Toxicity | Phase 1 | Terminatedsponsor's stated reason: Due to a Dose Limiting Toxicity. | Biological: BPX-601 · Drug: Rimiducid | Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer | 52 | 2016-11-30 | 2023-03-14actual | — | 2026-02-23 |
| MGNX | MacroGenics | $261M | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsNCT05551117results2026-02-09Part 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the Investigator | Phase 2 | Terminatedsponsor's stated reason: Business reasons | Biological: vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine · Drug: Abiraterone, Enzalutamide | Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma | 192 | 2023-06-13 | 2024-07-04actual | — | 2026-02-09 |
| PFE | Pfizer | $155.3B | Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in FinlandNCT05701007results2026-01-29observationalBody Mass Index (BMI) | — | Completed | Drug: abiraterone, enzalutamide, docetaxel, apalutamide, cabazitaxel, Radium-223, Lutetium-177, degarelix, goserelin, leuprorelin, triptorelin | Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC) | 1,083 | 2023-02-13 | 2024-04-10actual | — | 2026-01-29 |
| NUVB | Nuvation Bio Inc. | $2.4B | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid TumorsNCT06334432Phase 1: Assess safety and tolerability of NUV-1511 in advanced solid tumors | Phase 1/2 | Active, not recruiting | Drug: NUV-1511 | Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC) | 466 | 2024-03-14 | Mar 2027 | ≤ 223 d | 2026-01-14 |
| LLY | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | $1.15T | Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal TreatmentNCT04647526results2026-01-13Randomization Phase: Radiographic Progression-Free Survival (rPFS) | Phase 3 | Active, not recruiting | Drug: [Lu-177]-PNT2002, Abiraterone, Enzalutamide | Metastatic Castration-Resistant Prostate Cancer | 455 | 2021-02-25 | 2023-11-01actual | — | 2026-01-13 |
| EXEL | Exelixis | $13.2B | Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPCNCT01995058results2026-01-08Radiographic Progression Free Survival (PFS) | Phase 2 | Terminatedsponsor's stated reason: Sponsor decided to close the study prior to completion of enrollment. This was a business decision and not based on the safety results of the study. | Drug: cabozantinib, abiraterone, prednisone | Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms | 54 | Feb 2014 | Nov 2014actual | — | 2026-01-08 |
| LLY | Eli Lilly and Company | $1.15T | [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate CancerNCT06229366Maximum tolerated dose (MTD) | Phase 1 | Active, not recruiting | Drug: [Ac-225]-PSMA-62 (mCRPC), [Ac-225]-PSMA-62 (OmHSPC) | Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Oligometastatic Prostate Carcinoma, Hormone Sensitive Prostate Cancer | 142 | 2024-04-03 | Sep 2027 | ≤ 406 d | 2025-12-22 |
| NUVB | Nuvation Bio Inc. | $2.4B | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid TumorsNCT05252390Phase 1 Monotherapy Dose Escalation: Safety and tolerability of NUV-868 to determine the recommended Phase 2 dose (RP2D) | Phase 1 | Terminatedsponsor's stated reason: The Sponsor has achieved its objectives. | Drug: NUV-868, Olaparib, Enzalutamide | Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasm, Pancreatic Cancer, Pancreas Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Neoplasm, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Triple-negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor | 82 | 2022-03-29 | 2024-07-15actual | — | 2025-11-06 |
| AMGN | Amgen | $229.9B | Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPCNCT03792841Number of participants with dose-limiting toxicity | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: acapatamab, Pembrolizumab, Etanercept, Cytochrome P450 (CYP) Cocktail | Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | 212 | 2019-02-05 | 2023-06-29actual | — | 2025-10-16 |
| MGNX | MacroGenics | $261M | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsNCT05293496Number of participants with adverse events (AEs) | Phase 1 | Completed | Biological: vobramitamab duocarmazine, lorigerlimab | Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma | 31 | 2022-04-19 | 2025-06-24actual | — | 2025-10-14 |
| AMGN | Amgen | $229.9B | Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT04631601Dose exploration only: Number of participants who experience dose limiting toxicities (DLTs) | Phase 1/2 | Terminatedsponsor's stated reason: Amgen made a business decision to discontinue all AMG 160 clinical trials. This decision is not related to safety. | Drug: Acapatamab, Enzalutamide, Abiraterone, AMG 404 | Metastatic Castration-resistant Prostate Cancer | 65 | 2021-01-15 | 2023-10-23actual | — | 2025-10-07 |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs | Phase 1 | Recruiting | Drug: NX-1607, Paclitaxel | Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma | 345 | 2021-09-29 | 2026-08-31 | in 11 d | 2025-09-09 |
| EXEL | Exelixis | $13.2B | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsNCT03170960Dose Escalation: MTD/Recommended Dose | Phase 1 | Active, not recruiting | Drug: cabozantinib, atezolizumab, cabozantinib, cabozantinib | Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer | 914 | 2017-09-05 | 2023-02-21actual | — | 2025-08-17 |
| XNCR | Xencor, Inc. | $1.9B | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid TumorsNCT05585034Incidence of treatment-emergent adverse events (TEAEs) | Phase 1 | Completed | Biological: XmAb®808, Keytruda® (pembrolizumab) | Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Renal Cell Carcinoma, Clear Cell, Castration-resistant Prostate Cancer, Ovarian Cancer, Epithelial, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer | 60 | 2022-12-14 | 2025-05-20actual | — | 2025-08-07 |
| MGNX | MacroGenics | $261M | MGC018 With or Without MGA012 in Advanced Solid TumorsNCT03729596results2025-07-31Number of Patients With Adverse Events of Vobramitamab Duocarmazine as Assessed by CTCAE v4.03 | Phase 1/2 | Terminatedsponsor's stated reason: Business decision | Biological: vobramitamab duocarmazine | Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult, Metastatic Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer | 143 | 2018-11-21 | 2023-03-18actual | — | 2025-07-31 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate CancerNCT04381832Objective Response Rate (ORR) in Stage 1 and 2 | Phase 1/2 | Completed | Drug: Etrumadenant, Zimberelimab, Quemliclustat, Enzalutamide, Docetaxel, SG | Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Prostatic Cancer, Castration-Resistant | 173 | 2020-07-07 | 2024-08-30actual | — | 2025-07-22 |
| INCY | Incyte Corporation | $24.7B | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsNCT04580485Number of treatment-emergent adverse events (TEAE) | Phase 1 | Completed | Drug: INCB106385, INCMGA00012 | Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Castration Resistant Prostate Cancer, Colorectal Cancer, Gastric/ Gastroesophageal Junction, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Squamous Carcinoma of the Anal Canal | 54 | 2021-02-03 | 2024-01-22actual | — | 2025-07-11 |
| AMGN | Amgen | $229.9B | A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate CarcinomaNCT04740034results2025-06-17Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Terminatedsponsor's stated reason: Sponsor strategic decision | Drug: AMG 340 | Metastatic Castration-resistant Prostate Cancer | 42 | 2021-04-29 | 2024-06-24actual | — | 2025-06-17 |
| PFE | Pfizer | $155.3B | Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)NCT05650476expanded access | — | Available | Drug: Talazoparib | Metastatic Castration-Resistant Prostate Cancer | — | — | — | — | 2025-06-12 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate CancerNCT05169684results2025-06-10Number of Participants With Treatment Related Adverse Events | Phase 2 | Terminatedsponsor's stated reason: Business objectives have changed | Biological: BMS-986218, Nivolumab · Drug: Docetaxel | Prostatic Neoplasms, Castration-Resistant | 10 | 2022-02-14 | 2023-12-06actual | — | 2025-06-10 |
| CHRS | Coherus Oncology, Inc. | $207M | Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate CancerNCT05177770results2024-05-17Number of Participants With Response | Phase 2 | Terminatedsponsor's stated reason: The study was terminated for strategic reasons, not due to any safety concerns. | Drug: SRF617, etrumadenant, zimberelimab | Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | 16 | 2022-01-17 | 2023-04-05actual | — | 2025-05-08 |
| EXEL | Exelixis | $13.2B | Study of XB002 in Subjects With Solid Tumors (JEWEL-101)NCT04925284Dose-Escalation Stage: MTD/recommended dose for XB002 | Phase 1 | Completed | Drug: XB002, Nivolumab, Bevacizumab | Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors | 269 | 2021-06-07 | 2025-03-10actual | — | 2025-04-04 |
| KPTI | Karyopharm Therapeutics Inc | $44M | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer IndicationsNCT02649790Part A1, A2, B, C, D, E, F: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | Phase 1/2 | Completed | Drug: KPT-8602, ASTX727, Dexamethasone | Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS | 277 | Jan 2016 | 2024-08-31actual | — | 2025-03-19 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesNCT05032040PSA50 is the primary endpoint for the mCRPC cohort. Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumours (RECIST) version 1 criteria is the primary endpoint for gynecological malignancy cohorts | Phase 2 | Active, not recruiting | Biological: vudalimab | Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 170 | 2022-07-21 | 2025-10-15 | — | 2025-02-07 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100NCT01534052results2018-04-27Number of Participants With Adverse Events (AEs) | Phase 2 | Completed | Drug: Enzalutamide | Castration-Resistant Prostate Cancer (CRPC) | 52 | 2011-10-21 | 2017-04-18actual | — | 2024-12-06 |
| 4503.T | Astellas Pharma Inc | $26.0B | Long-Term Specified Drug Use-Results Survey for Xtandi CapsuleNCT02669771observationalIncidences of Adverse Events | — | Completed | Drug: enzalutamide | Castration-resistant Prostate Cancer | 1,018 | 2014-11-30 | 2018-11-30actual | — | 2024-11-21 |
| EXEL | Exelixis | $13.2B | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsNCT03845166Dose-Escalation Stage: MTD/recommended dose for XL092 | Phase 1 | Active, not recruiting | Drug: XL092, Atezolizumab, Avelumab | Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer | 325 | 2019-03-20 | 2026-08-31 | in 11 d | 2024-11-19 |
| CRDF | Cardiff Oncology | $69M | Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate CancerNCT03414034results2024-11-07Percentage of Participants Achieving Disease Control at or Before 12 Weeks | Phase 2 | Completed | Drug: Onvansertib, Abiraterone, Prednisone | Metastatic Castration-Resistant Prostate Cancer | 72 | 2018-08-14 | 2023-10-16actual | — | 2024-11-07 |
| PFE | Pfizer | $155.3B | Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT05520138results2024-09-27observationalOverall Survival (OS): Inverse Probability Treatment Weighting (IPTW) | — | Completed | Drug: Enzalutamide, Abiraterone acetate | Prostatic Neoplasms, Castration-Resistant | 5,506 | 2022-08-29 | 2023-06-30actual | — | 2024-09-27 |
| LLY | Eli Lilly and Company | $1.15T | Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate CancerNCT04408924results2023-05-24Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR]) | Phase 2 | Completed | Drug: Abemaciclib | Metastatic Castration-Resistant Prostate Cancer | 44 | 2021-01-20 | 2022-04-27actual | — | 2024-06-25 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced MalignanciesNCT03629756Percentage of participants with Adverse Events | Phase 1 | Completed | Drug: Etrumadenant, Zimberelimab | Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer, Melanoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Merkel Cell Carcinoma, GastroEsophageal Cancer, Renal Cell Carcinoma, Castration-resistant Prostate Cancer | 48 | 2018-07-24 | 2021-08-18actual | — | 2024-05-24 |
| EXEL | Exelixis | $13.2B | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)NCT04726332Dose-Escalation Stage: MTD/recommended dose for XL102 | Phase 1 | Terminatedsponsor's stated reason: Business reasons | Drug: XL102, Fulvestrant, Abiraterone, Prednisone | Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer | 52 | 2021-02-10 | 2024-05-02actual | — | 2024-05-14 |
| AZN | AstraZeneca | — | An Open-label, Phase II Study of AZD4635 in Patients With Prostate CancerNCT04089553results2022-07-08Percentage of Participants With Confirmed Objective Response Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | Phase 2 | Completed | Drug: AZD4635, Oleclumab, Durvalumab | Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 59 | 2019-08-29 | 2021-06-16actual | — | 2024-04-16 |
| VERU | Veru Inc. | $220M | Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting AgentNCT04844749Efficacy of VERU-111 in the treatment of metastatic castration-resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent | Phase 3 | Terminatedsponsor's stated reason: Administrative reasons | Drug: VERU-111, Enzalutamide, Abiraterone | Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer | 105 | 2021-06-24 | 2023-05-04actual | — | 2024-02-05 |
| IMUX | Immunic AG | $2.6B | IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate CancerNCT05124795Incidence and the grade (severity) of dose-limiting toxicities (DLTs) within 28 days after start of study treatment to identify the MTD and the RP2D | Phase 1 | Terminatedsponsor's stated reason: Lack of Efficacy | Drug: IMU-935 | Metastatic Castration Resistant Prostate Cancer | 18 | 2021-12-09 | 2023-05-31actual | — | 2024-01-17 |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.2B | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersNCT03454451Incidence of dose-limiting toxicities (DLTs) of CPI-006 as a single agent and in combination with ciforadenant and with pembrolizumab. | Phase 1 | Completed | Drug: CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab, CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab | Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma | 117 | 2018-04-25 | 2022-12-28actual | — | 2023-12-21 |
| PRLD | Prelude Therapeutics | $459M | A Study of PRT2527 in Participants With Advanced Solid TumorsNCT05159518Dose limiting toxicities (DLT) of PRT2527 | Phase 1 | Completed | Drug: PRT2527 | Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer, Solid Tumors With Known MYC Amplification | 30 | 2022-02-14 | 2023-12-06actual | — | 2023-12-11 |
| AZN | AstraZeneca | — | Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.NCT01972217results2018-10-02Part A: Percentage of Patients Experiencing Adverse Events (AEs) | Phase 2 | Completed | Drug: Olaparib, Placebo, Abiraterone, Prednisone or prednisolone | Metastatic Castration-resistant Prostate Cancer | 158 | 2014-04-01 | 2017-09-22actual | — | 2023-11-14 |
| IONS | Ionis Pharmaceuticals, Inc. | $9.9B | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)NCT01234025Progression free survival | Phase 1/2 | Completed | Drug: ISIS EIF4E Rx, ISIS EIF4E Rx, ISIS EIF4E Rx, Prednisone, Docetaxel | Castrate-Resistant Prostate Cancer | 113 | Nov 2010 | May 2013actual | — | 2023-10-06 |
| AZN | AstraZeneca | — | Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)NCT02987543results2020-10-12Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A Only | Phase 3 | Completed | Drug: olaparib, enzalutamide, abiraterone acetate, abiraterone acetate, enzalutamide | Metastatic Castration-resistant Prostate Cancer | 387 | 2017-02-06 | 2019-06-04actual | — | 2023-10-06 |
| VERU | Veru Inc. | $220M | To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate CancerNCT03752099Maximum Tolerated Dose | Phase 1/2 | Terminatedsponsor's stated reason: Administrative decision | Drug: VERU-111 | Metastatic Castration Resistant Prostate Cancer | 80 | 2019-01-18 | 2023-03-15actual | — | 2023-09-26 |
| NVO | Novo Nordisk A/S | — | A Study of FT-7051 in Men With MCRPCNCT04575766Incidence of dose limiting toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: FT-7051 | Metastatic Castration-resistant Prostate Cancer | 25 | 2020-12-30 | 2022-11-08actual | — | 2023-08-09 |
| NUVB | Nuvation Bio Inc. | $2.4B | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid TumorsNCT04541225Phase 1 Dose Escalation: Safety and tolerability of NUV-422 to determine the recommended Phase 2 dose (RP2D) | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: NUV-422 | Glioma, Glioma, Malignant, Glioma, Mixed, Glial Cell Tumors, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor, Malignant Tumor of Breast, Advanced Breast Cancer, Advanced Breast Carcinoma, Metastatic Breast Cancer, Metastatic Breast Carcinoma, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration-resistant Prostate Cancer, Castration Resistant Prostatic Neoplasms, Glioblastoma, Recurrent Glioblastoma | 74 | 2020-12-08 | 2022-08-31actual | — | 2023-07-14 |
| TPST | Tempest Therapeutics | $16M | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced CancersNCT03829436Incidence of dose limiting toxicities (DLTs) of TPST-1120 as a single agent and in combination with nivolumab. | Phase 1 | Completed | Drug: Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120, Part 4 TPST-1120 + nivolumab | Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma | 38 | 2019-03-20 | 2022-09-07actual | — | 2023-07-03 |
| AZN | AstraZeneca | — | HRR Prevalence in LatAm PROSPECT StudyNCT04962880observationalPrimary Outcome | — | Completed | — | Castration-resistant Prostate Cancer | 388 | 2021-04-21 | 2022-04-08actual | — | 2023-04-14 |
| AAPG | Ascentage Pharma Group Inc. | — | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or LymphomasNCT05415098Dose-limiting Toxicity (DLT) | Phase 1 | Unknown status | Drug: APG-5918 | Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma, Mesothelioma, Sarcoma, Non Hodgkin Lymphoma, B Cell Lymphoma, Epithelioid Sarcoma | 90 | 2022-09-30 | 2024-09-30 | — | 2022-11-16 |
| GOSS | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | $70M | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic AdenocarcinomaNCT04060342Phase 1 Dose Escalation - Regimens A, B,and C: Incidence of dose limiting toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Drug: GB1275, nab-paclitaxel and gemcitabine, pembrolizumab | Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma | 61 | 2019-08-13 | 2022-04-11actual | — | 2022-08-18 |
| NUVB | Nuvation Bio Inc. | $2.4B | Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPCNCT05191017Phase 1b Dose Escalation: Safety and tolerability of NUV-422 in combination with enzalutamide to determine the recommended Phase 2 combination dose (RP2cD) | Phase 1/2 | Withdrawnsponsor's stated reason: Sponsor decision | Drug: NUV-422, Enzalutamide | Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms | 0 | Sep 2022 | Jan 2025 | — | 2022-08-05 |
| PFE | Pfizer | $155.3B | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid TumorsNCT04052204results2021-10-14Number of Participants With Dose Limiting Toxicities (DLT) | Phase 1/2 | Terminatedsponsor's stated reason: Study prematurely terminated as the experimental treatments evaluated in study B9991040 may not provide additional clinical benefit over current or future Standard of Care in the different therapeutic indications that this trial was to evaluate. | Drug: avelumab, Bempegaldesleukin, talazoparib, enzalutamide | Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC) | 3 | 2019-12-30 | 2020-09-29actual | — | 2021-10-14 |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.2B | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced CancersNCT02655822Incidence of dose-limiting toxicities (DLTs) of ciforadenant as a single agent and in combination with atezolizumab | Phase 1 | Completed | Drug: Ciforadenant, Ciforadenant, Ciforadenant, Ciforadenant + atezolizumab, Ciforadenant | Renal Cell Cancer, Metastatic Castration Resistant Prostate Cancer | 502 | Jan 2016 | Jun 2021actual | — | 2021-08-30 |
| IPN.PA | Ipsen | $15.5B | Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate CancerNCT02057666results2021-04-23Time to Radiological Progression-Free Survival (PFS) | Phase 3 | Terminatedsponsor's stated reason: Development of tasquinimod in prostate cancer discontinued | Drug: Tasquinimod, Placebo | Prostatic Neoplasms, Castration-Resistant | 146 | Jan 2014 | May 2015actual | — | 2021-04-23 |
| PFE | Pfizer | $155.3B | A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)NCT02384382results2020-05-05Percentage of Participants With at Least (>=) 1 Responding Bone Lesion Assessed by Total Sodium Fluoride (NaF) Standardized Uptake Value [SUVtotal] at Third 18F-NaF PET/CT Imaging (NaF-3) Schedule | Phase 2 | Completed | Drug: Enzalutamide | Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer | 23 | 2015-11-30 | 2019-05-03actual | — | 2020-05-05 |
| IPN.PA | Ipsen | $15.5B | A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based ChemotherapyNCT01732549results2016-10-03Time to Radiological Progression Free Survival [PFS] | Phase 2 | Terminatedsponsor's stated reason: Development of tasquinimod in prostate cancer discontinued | Drug: Tasquinimod, Placebo | Metastatic Castrate Resistant Prostate Cancer | 144 | Jan 2013 | Feb 2015actual | — | 2019-11-22 |
| PFE | Pfizer | $155.3B | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.NCT00428220results2015-11-06Number of Participants With Treatment-emergent Adverse Events (AEs) (All Causalities) | Not applicable | Completed | Drug: sunitinib | Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer, Non-Small Cell Lung Cancer, Thyroid Cancer, Advanced/Metastatic Non-Small Cell Lung Cancer, Advanced Gastric Cancer, Gastrointestinal Stromal Tumor, Hepatocellular Carcinoma, Pancreatic Islet Cell Carcinoma, Pancreatic Neuroendocrine Tumor | 223 | Jul 2007 | Aug 2014actual | — | 2019-06-27 |
| PFE | Pfizer | $155.3B | Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based ChemotherapyNCT00974311results2012-10-30Overall Survival | Phase 3 | Completed | Drug: Enzalutamide, Placebo | Castration-Resistant Prostate Cancer | 1,199 | 2009-09-30 | 2011-09-15actual | — | 2018-12-11 |
| AMGN | Amgen | $229.9B | Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate CancerNCT00838201results2013-09-24Overall Survival Through Month 24 | Phase 3 | Completed | Drug: Denosumab | Cancer, Carcinoma, Castrate-Resistant Prostate Cancer, Prostate Cancer, Tumors | 384 | 2009-02-01 | 2012-05-03actual | — | 2018-10-18 |
| EXEL | Exelixis | $13.2B | Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate CancerNCT01522443results2018-05-23Pain Response at Week 6 Confirmed at Week 12, Week 12 Reported | Phase 3 | Terminatedsponsor's stated reason: Stopped after the outcome of cabozantinib Phase 3 CRPC study XL184-307. | Drug: cabozantinib, mitoxantrone, prednisone | Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms | 119 | Mar 2012 | Oct 2014actual | — | 2018-05-23 |
| EXEL | Exelixis | $13.2B | Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100NCT01605227results2018-03-14Overall Survival (OS) | Phase 3 | Completed | Drug: cabozantinib, prednisone | Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms | 1,028 | Jul 2012 | Sep 2014actual | — | 2018-03-14 |
| ACHV | Achieve Life Sciences | $774M | A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)NCT01083615To ascertain whether the investigational arm has a greater proportion of patients with durable pain palliation as compared to the control arm. | Phase 3 | Terminatedsponsor's stated reason: Unable to enroll due to criteria for stable baseline pain | Drug: custirsen sodium, isotonic, 0.9% sodium chloride, docetaxel, cabazitaxel, prednisone | Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer | 14 | Mar 2010 | Mar 2013actual | — | 2016-10-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Castration-Resistant Prostate Cancer is matched — 16 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Metastatic Castration-resistant Prostate Cancer
- Castration-resistant Prostate Cancer
- Metastatic Castration Resistant Prostate Cancer
- Castrate Resistant Prostate Cancer
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Prostatic Neoplasms, Castration-Resistant
- Castration Resistant Prostate Cancer
- Castrate-Resistant Prostate Cancer
- Castration Resistant Prostatic Cancer
- Castration Resistant Prostatic Neoplasms
- Castration-Resistant Prostate Cancer (CRPC)
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- mCRPC
- Castration-Resistant Prostatic Cancer
- Metastatic Castrate Resistant Prostate Cancer
- mCRPC (Metastatic Castration-resistant Prostate Cancer)
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Castration-Resistant Prostate Cancer” (a text search, wider than this page)